Life sciences company Element Biosciences sued Illumina on Monday in separate cases in federal courts in California and ...

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 5% on Monday after the company announced it received 510 (k) clearance from the U.S. Food and Drug Administration for its RNA-based Tempus xR ...

Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Molecular testing helps distinguish kidney cancer subtypes, ensuring patients get accurate diagnoses and treatment plans, ...

SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its ...

PacBio enters the high-throughput carrier screening market with a standalone HiFi sequencing assay for challenging genes.

Every season, scientists from the Institute of Science and Technology Austria (ISTA) go on field trips to the Pyrenees. Their ...

Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP ...

Tempus AI (TEM) announced it has received 510(k) clearance from the U.S. Food and Drug Administration for its RNA-based Tempus xR IVD device. The ...

Roche Holding AG - Special CallCompany ParticipantsBruno Eschli - Head of Investor RelationsTeresa Graham - Chief Executive Officer of ...

If future studies confirm the rescued receptors work normally, the study offers a new roadmap for rare disease drug development.